Daniela Bota, MD
Enriched profileProfessor, Department of Neurology, UC Irvine School of Medicine · University of California Irvine
Daniela Bota is Professor, Department of Neurology, UC Irvine School of Medicine at University of California Irvine. OpenAlex indexes 334 publications with 8,174 citations (h-index 41); ClinicalTrials.gov lists 7 registered studies with this person as an investigator.
Data verified 26 Oct 2026
Overview
Updated 27 Oct 2026
Daniela Bota, MD, is Professor, Department of Neurology, UC Irvine School of Medicine at University of California Irvine. The public record shows 334 publications with 8,174 citations (h-index 41), centered on Glioma Diagnosis and Treatment, Immunotherapy and Immune Responses, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 7 registered clinical trials, industry payments reported by 3 companies, 3 NIH-funded awards (2011–2025).
- Most recent indexed publication: 2026 · American journal of physiology. Cell physiology
- Top research focus: Glioma Diagnosis and Treatment
- 7 registered trials on ClinicalTrials.gov
- Open Payments reporting from 3 companies
Generated from the cited public record · current as of 27 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 86.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 26 Oct 2026
Listed as an investigator on 7 registered studies on ClinicalTrials.gov. The most recent:
- IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Sponsor: Ono Pharmaceutical Co., Ltd.
- Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT
Sponsor: University of California, Irvine
- Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ
Sponsor: University of California, Irvine
Industry payments
Updated 26 Oct 2026
3 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Neurocrine Biosciences, Inc.Program year20241 payment
- Telix PharmaceuticalsProgram year20222 payments
- Celularity Inc.Program year20211 payment
NIH funding
Updated 26 Oct 2026
3 NIH research awards on record, funded 2011–2025 per NIH RePORTER. The latest:
- Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
University of California-Irvine
FY2025$601,825R01CA263806 - Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
University of California-Irvine
FY2025$82,514R01CA263806 - Targeting p38/JNK MAPK to ameliorate cisplatin-induced adverse sequelae on the nervous system
University of California-Irvine
FY2025$80,303R01CA263806
Congress activity
Updated 26 Oct 2026
43 congress contributions (2006–2026) across AACR, ASCO, ASTRO per OpenAlex. The most recent:
- Abstract 3125: Transcriptomic analysis of glycosylation genes in chemotherapeutic-resistant glioma cells
AACR Annual Meeting
AACR2026Co-author - Abstract 382: Exploring the role of LONP1 in lon-traditional mechanisms of glioblastoma resistance.
AACR Annual Meeting
AACR2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 26 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Deciphering LonP1's role in glioblastoma: an alternative mechanism of treatment resistance.
American journal of physiology. Cell physiology
Article2026 - MAGMAS Inhibition Enhances Temozolomide Efficacy in Chemotherapy-Resistant Glioblastoma Models.
Cancer research communications
Article2026 - Glioma chemotherapeutic resistance is tied to membrane electrophysiological properties and glycosylation.
Bioengineering & translational medicine
Article2026 - The concept, intention, and evaluation of the term treatment-refractory meningioma.
Journal of neuro-oncology
Review2025
Most-cited works
by citation count (OpenAlex)Network
Updated 26 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 26 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
- verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
Secondary affiliations
appointments beyond the home institution- Chief Scientific Officer
Center for Clinical Research, UC Irvine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗ - Vice Dean
Clinical Research, UC Irvine School of Medicine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗ - Director
UCI Alpha Stem Cell Clinic
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗ - Vice Chair
Academic Affairs, Department of Neurology, UC Irvine
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗ - Medical Director
UCI Health Comprehensive Brain Tumor Program
verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ucihealth.org ↗
Media & interviews
press, podcasts and appearances- UC Irvine news coverage (2012) of brain tumor vaccine trials
reposting an Orange County Register interview
2012verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →news.uci.edu ↗ - CBS Los Angeles segment on glioblastoma
quoting Dr. Bota on why the tumor is hard to treat
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cbsnews.com ↗ - OncologyTube interview on glioblastoma symptoms
clinical trials and treatment options (McCain diagnosis)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →oncologytube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Guy McKhann, MD
Emory University School of Medicine
Patrick Wen, MD
Dana-Farber Cancer Institute
Minesh Mehta, MD
Florida International University Herbert Wertheim College of Medicine
Timothy Cloughesy, MD
Ronald Reagan UCLA Medical Center